NCT05429866 2023-03-08
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Jules Bordet Institute
Phase 2 Unknown
Clinical Trials
6 trialsNCT05312216 2023-01-26
Durvalumab Plus Lenvatinib as First-line Treatment for Unresectable Hepatocellular Carcinoma
Zhejiang University
Phase 2 Unknown
NCT04961918 2021-07-14
The Efficacy of Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Durvalumab (HILL) in Advanced Hepatocellular Carcinoma (HCC)
Sun Yat-sen University
Phase 2 Unknown
NCT04913480 2021-06-04
SBRT and Durvalumab for Inoperable/Unresectable Hepatocellular Carcinoma
The University of Hong Kong
Phase 2 Unknown
NCT04517227 2021-05-03
The Combination Therapy of TACE and Ablation With Durvalumab in Hepatocellular Carcinoma at Intermediate Stage (TAD)
Fudan University
Phase NA Unknown
NCT04443322 2020-09-22
Dulect2020-1
RenJi Hospital
Phase NA Unknown